Kleiner Device Labs Featured in Benzinga & Becker’s Spine Review

This article is brought to you by Equifund Technologies, LLC.

Share on facebook
Share on twitter
Share on linkedin

Last week, Kleiner Device Labs (KDL) picked up two media mentions worth mentioning…

First came from the financial publisher Benzinga titled “This Medical Startup Could Disrupt The $14 Billion Spinal Fusion Market: Last Call To Invest.”

The second came from a well known industry publication called Becker’s Spine Review titled “Spine surgeon’s startup wants a slice of the $14B spinal fusion market.”

If you’ve been following the KDL story, you already know that Dr. Kleiner – the founder and CEO – has performed over 6,000 spinal surgeries during his 25 year career.

He also has personally had three spinal surgeries performed on him as a patient!

Not only that, but he’s invested $2 million of his own money and has his name sake on the company.

Why should investors care? All things considered, investing in founders with this much ”skin in the game” – both financially and reputationally – is preferable to the opposite.

And perhaps more importantly, he’s been able to recruit a team of industry veterans to help lay the foundation for future growth.

According to management:

The two largest costs for KDL that will directly translate to success are product development and building a salesforce.

From a cost perspective, the KDL team has been highly effective at developing products.

According to Pitchbook, the average cost of developing a MedTech device and achieving 510(k) Clearance is $31 million.

According to Management, they’ve deployed ~$5m total to develop two devices that have achieved 510(k) Clearance!

Not to mention the 23 patents they’ve acquired to secure their technology.

But it’s not enough to simply “build a better mousetrap”…

In order to create shareholder value, the company needs to effectively sell their products into a complex sales cycle.

That’s why they hired Mike Hughes to be their Chief Commercial Officer!

Not only does Mike bring his two decades of experience building medical sales teams, he brings a rolodex of potential customers and industry contacts.

Watch Equifund interview Mike here

Considering an Investment in Kleiner Device Labs?

If so, you’ll want to review their offering listed on the Equifund Crowd Funding Portal by going here. 

Currently, KDL can raise up to $1.07 million under their current Form-C filing (they are currently at ~$850k in commitments).

Management has also indicated they will be closing this round once the first surgery has been completed with the new KG2.

They may or may not continue to raise more capital via regulation crowdfunding.

Put another way, this may be your last chance to invest in Kleiner Device Labs at the current valuation.


Jake Hoffberg

Jake Hoffberg – Publisher

Like this article? Share it with a friend:

Share on facebook
Share on twitter
Share on linkedin

This article is not an Equifund Crowd Funding Portal Inc communication. It is brought to you by Equifund Technologies, LLC.

More Articles:

Don't make another private market investment without reading this...

The 5 Mistakes

investors make that crush returns

Download this free report now:

Just enter your name & email to access this report for free.

By submitting your email address you will receive access to this report and a free subscription to Equifund’s private investment newsletter. You can unsubscribe at any time and read more about our privacy policy here.

More Articles:


Kleiner Device Labs

Investment Highlights:

  • 1

    Proprietary devices that could revolutionize spinal surgery and greatly improve success rates, reduce pain, and lower costs.

  • 2

    Over 20 patents have been issued to protect the company's technologies.

  • 3

    Just received FDA clearance for their next-generation KG2 spinal fusion technology.

Pre-Investment Agreement

The next 8 slides will allow us to process your investment. Note that these next steps are a legal requirement – Thank you for your patience and financial support of this investment opportunity. Jordan Gillissie – CEO

Before we execute the investment, it’s important for us to make sure you’re comfortable and knowledgeable in early stage investing. We want to make sure that you:

    • Received and have reviewed the education materials sent to you.
    • UNDERSTAND; that there are restrictions on your ability to cancel your investment commitment and obtain a return of your investment.
    • KNOW; It may be difficult to resell securities acquired under Regulation Crowdfunding.
    • AGREE; investing in securities offered and sold in reliance on section 4(a)(6) of the Securities Act involves risk. Investors should not invest any funds unless he or she can afford to lose the entire amount of his or her investment. Your investment may not work out, and you must be in a financial condition to bear the loss.
  • Hidden
  • Hidden
  • Hidden
  • Hidden

We are currently upgrading our system. If you click submit and the process does not continue in a few seconds, please refresh this page manually, and click Invest Now again and you should be moved on to the next step.

Complete Your Registration

By verifying your account you agree with our terms of use, privacy policy and pre-dispute arbitration agreement. Please complete the registration process by clicking the link below:

Verify Your Email

Please wait a few minutes while we create your account. An email will be sent to you shortly to confirm your admittance. Should the email be delivered to your spam or promotions folder, we recommend you move it to your inbox and mark Equifund as a safe sender.

If you have not received the email in 5 minutes, please click here to have it resent.

Questions? Our customer service team is always here to help – 1-866-338-3004

Enter your email address to get instant access to the video: